RISVAN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RISVAN (RISVAN).
Risperidone is an atypical antipsychotic that acts as a serotonin 5-HT2A and dopamine D2 receptor antagonist. It also binds to alpha1-adrenergic and H1 histaminergic receptors.
| Metabolism | Primarily metabolized by CYP2D6 to 9-hydroxyrisperidone (active metabolite), with minor contribution from CYP3A4. |
| Excretion | Renal: 30% unchanged; Fecal: 65% (biliary excretion of metabolites); 5% other. |
| Half-life | Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 20-30 hours in hepatic impairment (Child-Pugh B/C). |
| Protein binding | 97% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6 L/kg (suggests moderate tissue distribution; not extensively sequestered). |
| Bioavailability | Oral: 85% (not significantly affected by food). |
| Onset of Action | Oral: 1-2 hours; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 12-24 hours (dose-dependent); Intravenous: 4-6 hours (single dose). Duration extends with accumulation in chronic use. |
| Molecular Weight | 410.5 |
70 mg orally once daily, with or without food.
| Dosage form | FOR SUSPENSION, EXTENDED RELEASE |
| Renal impairment | eGFR 30-89 mL/min: No adjustment. eGFR <30 mL/min or dialysis: Not recommended. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B or C: Not recommended. |
| Pediatric use | Not approved for use in pediatric patients. |
| Geriatric use | No specific dose adjustment; use caution due to age-related renal impairment. |
| 1st trimester | Risperidone (the active ingredient in RISVAN) crosses the placenta. First-trimester exposure is associated with a small increased risk of congenital malformations, particularly cardiac defects. Use only if benefit outweighs risk. |
| 2nd trimester | Second-trimester exposure may be associated with preterm delivery and low birth weight. Monitor growth and development. Use if clearly needed. |
| 3rd trimester | Third-trimester exposure can lead to extrapyramidal symptoms and withdrawal in the neonate, including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorder. Taper dose if possible before delivery. |
Clinical note
Comprehensive clinical and safety monograph for RISVAN (RISVAN).
| Placental transfer | Risperidone crosses the placenta. The cord-to-maternal plasma concentration ratio is approximately 0.5-0.7 for risperidone and 0.4-0.6 for 9-hydroxyrisperidone, indicating significant transfer. |
| Breastfeeding |
■ FDA Black Box Warning
Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Risperidone is not approved for the treatment of dementia-related psychosis.
| Serious Effects |
Hypersensitivity to risperidone or any excipients
| Precautions | Neuroleptic malignant syndrome, tardive dyskinesia, stroke in elderly dementia patients, hyperglycemia/diabetes, weight gain, hyperprolactinemia, orthostatic hypotension, seizures, leukopenia/neutropenia, and body temperature dysregulation. |
| Food/Dietary | Avoid grapefruit and grapefruit juice; inhibits CYP3A4 and may increase drug levels. Limit alcohol as it may exacerbate CNS depression. No specific restrictions with other foods. |
Loading safety data…
| Risperidone and its active metabolite 9-hydroxyrisperidone are excreted in human milk at low levels. The infant dose is estimated at 2-4% of the maternal weight-adjusted dose. Monitor for sedation, irritability, and poor weight gain. Benefit of breastfeeding should outweigh possible risks. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | RISVAN is contraindicated in pregnancy due to teratogenicity. First trimester: High risk of major congenital malformations including neural tube defects, cardiovascular anomalies, and cleft palate. Second/third trimester: Risk of fetal growth restriction, preterm birth, and neurodevelopmental impairment. Fetal toxic effects include encephalopathy and intrauterine death. |
| Fetal Monitoring | Maternal: CBC, hepatic and renal function tests, serum drug levels, vital signs, ECG. Fetal: Ultrasound for growth and anatomy, fetal heart rate monitoring, biophysical profile. Neonatal: Observation for withdrawal symptoms, respiratory status, blood glucose. |
| Fertility Effects | May impair female fertility by disrupting menstrual cycle and reducing ovarian reserve. In males, may cause oligospermia and reduced sperm motility. Reversible upon discontinuation. |
| Clinical Pearls | RISVAN is a brand name for risperidone. Avoid concomitant use with CYP2D6 inhibitors (e.g., fluoxetine) or strong CYP3A4 inducers. Monitor for orthostatic hypotension, especially during dose titration. Risk of QT prolongation; obtain baseline ECG in elderly or those with cardiac disease. Observe for extrapyramidal symptoms and tardive dyskinesia. May elevate prolactin levels; monitor for gynecomastia, galactorrhea, or menstrual irregularities. |
| Patient Advice | Take as prescribed; do not stop abruptly. · Avoid alcohol and grapefruit juice. · Rise slowly from sitting or lying to prevent dizziness. · Report symptoms like muscle stiffness, tremor, or uncontrolled movements. · May cause drowsiness; avoid driving if affected. · Monitor weight and blood sugar regularly. · Notify doctor if you experience breast swelling, discharge, or sexual dysfunction. |